{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:10:10Z","timestamp":1783825810872,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-112-2314-B-005-011"],"award-info":[{"award-number":["NSTC-112-2314-B-005-011"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1103701C"],"award-info":[{"award-number":["TCVGH-1103701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1083701C"],"award-info":[{"award-number":["TCVGH-1083701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1113701C"],"award-info":[{"award-number":["TCVGH-1113701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1103701D"],"award-info":[{"award-number":["TCVGH-1103701D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.taap.2025.117449","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:30:41Z","timestamp":1750386641000},"page":"117449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Alisertib inhibits acute myeloid leukemia cell growth by inhibiting STAT3 activation"],"prefix":"10.1016","volume":"502","author":[{"given":"Pang-Ting","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Pei","family":"Jhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Rung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Lin Jerry","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2025.117449_bb0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2021013201","article-title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","volume":"139","author":"Amaya","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.taap.2025.117449_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2025.117449_bb0015","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(19)30203-0","article-title":"Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Brunner","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.taap.2025.117449_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117449_bb0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/2040620715607415","article-title":"Recent advances in the development of Aurora kinases inhibitors in hematological malignancies","volume":"6","author":"Choudary","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.taap.2025.117449_bb0030","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/1078-0432.CCR-09-1445","article-title":"A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors","volume":"15","author":"Cohen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2025.117449_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.taap.2025.117449_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","article-title":"A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer","volume":"20","author":"Diamond","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.taap.2025.117449_bb0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2025.117449_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.taap.2025.117449_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1873-3468.14985","article-title":"Age-associated myeloid malignancies - the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia","volume":"598","author":"Fasouli","year":"2024","journal-title":"FEBS Lett."},{"key":"10.1016\/j.taap.2025.117449_bb0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2025.117449_bb0065","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1158\/0008-5472.CAN-15-3253","article-title":"Cdk5 directly targets nuclear p21CIP1 and promotes cancer cell growth","volume":"76","author":"Huang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2025.117449_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.taap.2025.117449_bb0075","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41419-024-07044-3","article-title":"SPHK1 promotes bladder cancer metastasis via PD-L2\/c-Src\/FAK signaling cascade","volume":"15","author":"Kao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2025.117449_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.taap.2025.117449_bb0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","article-title":"Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors","volume":"27","author":"Liewer","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.taap.2025.117449_bb0090","doi-asserted-by":"crossref","first-page":"52175","DOI":"10.1074\/jbc.M406802200","article-title":"Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215","volume":"279","author":"Liu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2025.117449_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155735","article-title":"Securinine inhibits carcinogenesis in gastric cancer by targeting AURKA-beta-catenin\/Akt\/STAT3 and the cell cycle pathway","volume":"130","author":"Lv","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.taap.2025.117449_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21873\/cdp.10016","article-title":"The relevance of Aurora kinase inhibition in hematological malignancies","volume":"1","author":"Machado","year":"2021","journal-title":"Cancer Diagn. Progn."},{"key":"10.1016\/j.taap.2025.117449_bb0105","first-page":"516","article-title":"A non-mitotic role for Aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src","volume":"128","author":"Mahankali","year":"2015","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.taap.2025.117449_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2024.142124","article-title":"Impact of metformin on neocortical development during pregnancy: involvement of ERK and p35\/CDK5 pathways","volume":"358","author":"Oner","year":"2024","journal-title":"Chemosphere"},{"key":"10.1016\/j.taap.2025.117449_bb0115","first-page":"C1648","article-title":"Metformin inhibits nerve growth factor-induced sympathetic neuron differentiation through p35\/CDK5 inhibition","volume":"326","author":"Oner","year":"2024","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.taap.2025.117449_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149874","article-title":"Metformin alters dendrite development and synaptic plasticity in rat cortical neurons","volume":"710","author":"Oner","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2025.117449_bb0125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21873\/anticanres.16842","article-title":"p35\/CDK5 regulates bladder cancer proliferation and migration and promotes higher tumor grade and poor survival rate in patients with bladder cancer","volume":"44","author":"Oner","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.taap.2025.117449_bb0130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Sanchez-Correa","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.taap.2025.117449_bb0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.taap.2025.117449_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1034\/j.1600-0609.2001.t01-1-00385.x","article-title":"Constitutive activation of STAT transcription factors in acute myelogenous leukemia","volume":"67","author":"Spiekermann","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.taap.2025.117449_bb0145","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/bloodadvances.2017007856","article-title":"Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance","volume":"1","author":"Stevens","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.taap.2025.117449_bb0150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2025.117449_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231154708","article-title":"Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia","volume":"14","author":"Swaminathan","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.taap.2025.117449_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2023.105768","article-title":"Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1\/STAT3\/MYC pathways","volume":"96","author":"Teng","year":"2024","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.taap.2025.117449_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000914","article-title":"An overview of targeted therapies in acute myeloid leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.taap.2025.117449_bb0170","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/med.21399","article-title":"Aurora-A kinase: a potent oncogene and target for cancer therapy","volume":"36","author":"Yan","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.taap.2025.117449_bb0175","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of Aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2500225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2500225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:28:58Z","timestamp":1753205338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X2500225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"alternative-id":["S0041008X2500225X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117449","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alisertib inhibits acute myeloid leukemia cell growth by inhibiting STAT3 activation","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117449"}}